• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Molecular Templates Inc. (Amendment)

    4/29/24 9:51:58 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTEM alert in real time by email
    SC 13D/A 1 d711815dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    MOLECULAR TEMPLATES, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    608550 109

    (CUSIP Number)

    Patrick G. Enright

    Managing Member

    Longitude Capital Partners III, LLC

    2740 Sand Hill Road, 2nd Floor

    Menlo Park, CA 94025

    (650) 854-5700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 25, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 608550 109      13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Capital Partners III, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     309,819 (1)(2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     309,819 (1)(2)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     309,819 (1)(2)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.6% (3)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    All of such securities are held of record by Longitude Venture III (as defined in the Explanatory Note below). Longitude Capital III (as defined in the Explanatory Note below) is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 213,268 outstanding shares of Common Stock, and (b) 96,551 shares of Common Stock issuable upon exercise of Warrants.

    (3)

    The percentage was calculated based on 6,680,431 shares of Common Stock, as follows: (a) 6,583,880 shares of Common Stock outstanding as of April 22, 2024 as reported by the Issuer in its Annual Report on Form 10-K/A as filed with the Securities and Exchange Commission on April 25, 2024 (the “Form 10-K”); plus (b) 96,551 shares of Common Stock issuable upon exercise of the Warrants held of record by Longitude Venture III.


    CUSIP No. 608550 109      13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Longitude Venture Partners III, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     309,819 (1)(2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     309,819 (1)(2)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     309,819 (1)(2)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.6% (3)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    All of such securities are held of record by Longitude Venture III. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 213,268 outstanding shares of Common Stock, and (b) 96,551 shares of Common Stock issuable upon exercise of Warrants.

    (3)

    The percentage was calculated based on 6,680,431 shares of Common Stock, as follows: (a) 6,583,880 shares of Common Stock outstanding as of April 22, 2024 as reported by the Issuer in its Form 10-K; plus (b) 96,551 shares of Common Stock issuable upon exercise of the Warrants held of record by Longitude Venture III.


    CUSIP No. 608550 109      13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Patrick G. Enright

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     233 (1)

        8  

     SHARED VOTING POWER

     

     309,819 (2)(3)

        9  

     SOLE DISPOSITIVE POWER

     

     233 (1)

       10  

     SHARED DISPOSITIVE POWER

     

     309,819 (2)(3)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     310,052 (1)(2)(3)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.6% (4)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    These shares are held by a limited partnership (the “Partnership”) of which the general partner is a trust (the “Enright Trust”). Mr. Enright is the Trustee of the Enright Trust and may be deemed to share voting, investment and dispositive power over the shares held by the Partnership.

    (2)

    All of such securities are held of record by Longitude Venture III. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (3)

    Consists of (a) 213,268 outstanding shares of Common Stock and (b) 96,551 shares of Common Stock issuable upon exercise of Warrants.

    (4)

    The percentage was calculated based on 6,680,431 shares of Common Stock, as follows: (a) 6,583,880 shares of Common Stock outstanding as of April 22, 2024 as reported by the Issuer in its Form 10-K; plus (b) 96,551 shares of Common Stock issuable upon exercise of the Warrants held of record by Longitude Venture III.


    CUSIP No. 608550 109      13D

     

     1   

     NAMES OF REPORTING PERSONS

     

     Juliet Tammenoms Bakker

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS (see instructions)

     

     OO

     5  

     CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7   

     SOLE VOTING POWER

     

     0

        8  

     SHARED VOTING POWER

     

     309,819 (1)(2)

        9  

     SOLE DISPOSITIVE POWER

     

     0

       10  

     SHARED DISPOSITIVE POWER

     

     309,819 (1)(2)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     309,819 (1)(2)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

     4.6% (3)

    14  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    All of such securities are held of record by Longitude Venture III. Longitude Capital III is the general partner of Longitude Venture III and may be deemed to have voting, investment and dispositive power with respect to these securities. Patrick G. Enright and Juliet Tammenoms Bakker are the managing members of Longitude Capital III and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (a) 213,268 outstanding shares of Common Stock and (b) 96,551 shares of Common Stock issuable upon exercise of Warrants.

    (3)

    The percentage was calculated based on 6,680,431 shares of Common Stock, as follows: (a) 6,583,880 shares of Common Stock outstanding as of April 22, 2024 as reported by the Issuer in its Form 10-K; plus (b) 96,551 shares of Common Stock issuable upon exercise of the Warrants held of record by Longitude Venture III.


    Explanatory Note:

    This joint statement on Schedule 13D/A is filed with respect to the common stock, par value $0.001 per share (“Common Stock”), of Molecular Templates, Inc., a Delaware corporation (the “Issuer”).

    This Amendment No. 6 to Schedule 13D (“Amendment No. 6”) amends and supplements the Schedule 13D initially filed with the Securities and Exchange Commission (the “Commission”) on September 18, 2017, as amended by Amendment No. 1 filed with the Commission on September 26, 2018 (“Amendment No. 1”), Amendment No. 2 filed with the Commission on December 5, 2019 (“Amendment No. 2”), Amendment No. 3 filed with the Commission on June 5, 2020 (“Amendment No. 3”), Amendment No. 4 filed with the Commission on February 14, 2023 (“Amendment No. 4”) and Amendment No. 5, filed with the Commission on October 24, 2023 (“Amendment No. 5” and together with Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5, the “Original Schedule 13D”). This Amendment No. 6 is being filed to update the aggregate percentage of the Issuer’s Common Stock owned by the Reporting Persons due to dilution caused by, among other things, the Issuer’s sales of additional shares of its Common Stock from time to time since the date of the filing of the Original Schedule 13D and not in connection with a disposition of any shares by the Reporting Persons. Such dilution resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Original Schedule 13D. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Original Schedule 13D is hereby amended to add the following language:

    (a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.

    (e) On April 25, 2024, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of the outstanding shares of Common Stock.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: April 29, 2024.

     

    LONGITUDE VENTURE PARTNERS III, L.P.

    By: LONGITUDE CAPITAL PARTNERS III, LLC

    Its: General Partner

      
    By:   

    /s/ Cristiana Blauth Oliveira

      
       Cristiana Blauth Oliveira, Authorized Signatory   
    LONGITUDE CAPITAL PARTNERS III, LLC   
    By:   

    /s/ Cristiana Blauth Oliveira

      
       Cristiana Blauth Oliveira, Authorized Signatory   

     

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright

      
    Patrick G. Enright   

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker

      
    Juliet Tammenoms Bakker   
    Get the next $MTEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Molecular Templates with a new price target

      BofA Securities initiated coverage of Molecular Templates with a rating of Buy and set a new price target of $12.00

      4/21/21 6:52:47 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Molecular Templates with a new price target

      UBS initiated coverage of Molecular Templates with a rating of Neutral and set a new price target of $13.00

      2/1/21 7:51:02 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    SEC Filings

    See more
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      1/2/25 4:13:52 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Molecular Templates Inc.

      8-K - Molecular Templates, Inc. (0001183765) (Filer)

      12/19/24 4:11:29 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Molecular Templates Inc.

      DEFA14A - Molecular Templates, Inc. (0001183765) (Filer)

      12/4/24 4:10:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Target N V bought $587,500 worth of shares (250,000 units at $2.35), increasing direct ownership by 24% to 1,279,820 units (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      4/4/24 8:13:35 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Target N V sold $845,833 worth of shares (1,279,820 units at $0.66), closing all direct ownership in the company (SEC Form 4)

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      11/18/24 9:12:24 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lalande Kevin M.

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:41:36 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gruia Gabriela

      4 - Molecular Templates, Inc. (0001183765) (Issuer)

      9/30/24 5:37:40 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/18/24 9:49:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/14/24 4:37:56 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

      SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

      11/12/24 9:31:46 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

      AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a "public shell," and that, in the view of the Staff, the continued listing of the

      12/19/24 4:10:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

      AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or the "Company")), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced that it has received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") on November 25, 2024. The notice indicated that MTEM is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of

      12/2/24 5:06:43 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTEM
    Leadership Updates

    Live Leadership Updates

    See more
    • Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the succession of its Chief Executive Officer ("CEO"), Allan Camaisa, to Eric Poma, Ph.D., who was appointed as CEO and member of the Board of Directors of Calidi ("Board"), effective April 22, 2025. Mr. Camaisa will continue to serve as a member of the Board. "We are pleased to welcome Eric as Calidi's new CEO, given his deep experience in life science leadership with a focus on oncology, as Calidi advances its systemic enveloped virotherapy platform to the clinic and prepa

      4/23/25 8:00:00 AM ET
      $CLDI
      $MTEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

      AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM"))), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023. Dr. Voi joins MTEM from Novartis, where he served as Vice President, Global Program Head, for the PD-1 antibody Tislelizumab since April 2021. He was previously Global Program Head, Melanoma, at Novartis, a pos

      9/28/23 4:11:00 PM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Molecular Templates Strengthens Board of Directors and Management Team

      Industry Veteran Gabriela Gruia, M.D., appointed to Board of Directors Megan Filoon promoted to General Counsel AUSTIN, Texas, March 02, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (NASDAQ:MTEM, "Molecular Templates, " or "MTEM" or "the Company"))), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced the appointment of Gabriela Gruia, M.D., to its Board of Directors and the promotion of Megan Filoon to General Counsel. "Dr. Gruia brings a wealth of industry knowledge to our Board of Directors," said Barry Selick, Ph.D., Chairman of the Board of Molecular

      3/2/22 8:00:00 AM ET
      $MTEM
      Biotechnology: Pharmaceutical Preparations
      Health Care